Absea Biotech
banner
abseabio.bsky.social
Absea Biotech
@abseabio.bsky.social
Absea Biotechnology | Empowering protein science

14,000+ recombinant proteins & 11,000+ monoclonal antibodies covering 70% of the human proteome.

Germany-USA-China
https://www.absea.bio/index.html
📩 Contact us: [email protected]
🌐 Learn more: www.absea.bio
November 25, 2025 at 10:41 AM
- Validation data behind Absea’s #neuroscience:
www.absea.bio/product-anti...

- Performed by Fornasiero Laboratory, University of Göttingen (UMG):
www.fornasierolab.uni-goettingen.de

Get in touch directly to discuss your needs and potential collaborations: [email protected]
Absea-Absea Biotechnology Ltd.
Absea develops, engineers and characterizes protein and antibody reagents with unprecedented throughput and quality. We strive to provide products, services and tools to break new ground in protein re...
www.absea.bio
November 20, 2025 at 10:56 AM
Want to see IP-MS validation results or protocol details?
We’re happy to share!
Message us or check out Pullroven® on Absea’s site: www.absea.bio/index.html
Absea-Absea Biotechnology Ltd.
Absea develops, engineers and characterizes protein and antibody reagents with unprecedented throughput and quality. We strive to provide products, services and tools to break new ground in protein re...
www.absea.bio
October 21, 2025 at 9:32 AM
October 9, 2025 at 9:35 AM
October 9, 2025 at 9:35 AM
Source: European Centre for Disease Prevention and Control (12-month Chikungunya virus disease case notification rate per 100 000 population, September 2024-August 2025).
October 2, 2025 at 9:41 AM